AstraZeneca bought Belgian biotech company EsoBiotec in a deal valued at up to $1 billion, to expand its cell-therapy portfolio. The British pharma company said Monday that it will pay $425 ...

AstraZeneca Plc, the UK drugmaker, agreed to buy the Belgian biotech EsoBiotec for as much as $1 billion to further boost its cancer capabilities. AstraZeneca will pay $425 million upfront and ...

So far, the practice has been rare among European and UK non-financial corporate issuers, but D&I firms hope AstraZeneca's deal will pave the way for wider adoption across the pond. “We are so ...

AstraZeneca has announced two separate deals that will see the company acquire EsoBiotec for up to $1 billion as well as a licensing deal with Alteogen that will expand its work in oncology and cell ...